Ind-Swift Laboratories Limited

Ind-Swift Laboratories Schedules Investor Meet on Jan 23, 2026

Ind-Swift Laboratories Limited will hold a virtual one-to-one investor meet with Omkara Capital on January 23, 2026. No Unpublished Price Sensitive Information will be shared during the meeting.

Ind-Swift Labs Unveils Investor Presentation Highlighting Strategic Transformation and Future Growth

Ind-Swift Labs has divested its API & CRAMS business for ₹1,650 crore, becoming net debt-free. The company targets doubling revenue by FY29, driven by exports and a Viatris partnership starting FY27. Q2 FY26 revenue was ₹170.50 crore, with EBITDA at ₹19.34 crore.

Ind-Swift Laboratories Files SEBI Compliance Certificate for Q3 FY26

Ind-Swift Laboratories Limited submitted a SEBI compliance certificate for the quarter ended December 31, 2025. The certificate, received from the Registrar and Share Transfer Agent, confirms dematerialization of securities and adherence to SEBI regulations.

Ind-Swift Laboratories: Trading Window Closes Jan 1, 2026, for Q3 FY26 Results

Ind-Swift Laboratories Limited will close its trading window from January 1, 2026. The closure is until 48 hours after the declaration of Q3 FY26 unaudited standalone and consolidated financial results. This is in compliance with SEBI insider trading regulations.

Ind-Swift Laboratories: Promoter family transfers 2,32,057 shares

Ind-Swift Laboratories Limited reports the transmission of 2,32,057 equity shares from Late Mrs. Neera Mehta to her legal heirs, Rishav Mehta, Ishav Mehta, and Daksh Mehta. This transfer, completed on December 17, 2025, is under SEBI SAST Regulations exemption. The promoter group's aggregate shareholding remains unchanged.

Ind-Swift Labs: Transmission of 2.32 Lakh Shares Completed for Late Neera Mehta's Heirs

Ind-Swift Laboratories Limited completed the transmission of 2,32,057 equity shares for the legal heirs of the late Mrs. Neera Mehta. The transmission was made under SEBI SAST Regulations exemption. The shares are now in the joint demat account of Rishav Mehta, Ishav Mehta, and Daksh Mehta.

Ind-Swift Labs Receives GMP Certificate from Hungary, Opens European Markets

Ind-Swift Laboratories received a GMP certificate from Hungary following a November 2025 inspection. The certificate is valid for three years and opens European markets. The company also holds WHO-GMP, TGA, MHRA, SAPRA, and EU-GMP certifications.

Ind-Swift Laboratories Appoints Senior Management Personnel

Ind-Swift Laboratories appoints Dinesh Kashikar as VP- Site Quality Head and Vinayak N. Malik as Sr. General Manager (Quality Control), effective December 8, 2025.

Trading Approval Received for Amalgamation Scheme

Ind-Swift Laboratories received trading approval from BSE and NSE for 81,24,698 equity shares of ₹10 each allotted on August 25, 2025, pursuant to the Amalgamation Scheme.

Ind-Swift Laboratories Receives ISO 14001:2015 and ISO 45001:2018 Certifications

Ind-Swift Laboratories' unit receives ISO 14001:2015 and ISO 45001:2018 certifications, demonstrating commitment to environmental sustainability and occupational health and safety.

Monitoring Agency Report reveals fund utilization deviations for preferential issue in Q2FY26

Monitoring agency report for Ind-Swift Laboratories reveals ₹45.21 crore reimbursement deviation and ₹64.09 crore investment in a third-party NBFC from preferential issue funds.

Ind-Swift Labs Approves Unaudited Results, Investment in AIFs

Ind-Swift Labs approves unaudited financial results for the quarter ended September 30, 2025, and authorizes an investment of up to ₹51 crore in SEBI-registered Alternative Investment Funds (AIFs).

Ind-Swift Laboratories: NSE Approves Listing of Amalgamated Shares; BSE Approval Awaited

Ind-Swift Labs provided an update on the listing of shares post-amalgamation. NSE approved listing on October 10, 2025. BSE approval is awaited, after which shares will be credited and trading enabled.

Ind-Swift Laboratories Submits SEBI Regulation 74(5) Certificate for Q2 FY26

Ind-Swift Laboratories submitted a certificate under SEBI Regulation 74(5) for the quarter ended 30th September, 2025, confirming dematerialization compliance.

Voting Results of 30th AGM of Ind-Swift Laboratories Limited

INDSWFTLAB: Outcome of 30th AGM held on 29 Sep 2025

Ind-Swift Labs to form JV for Chandigarh Premier League

Ind-Swift Labs: Promoters Transfer 2.49 Lakh Shares via Transmission

Ind-Swift Laboratories Reports Significant Q1 FY26 Profit Decline Amid Amalgamation Finalization

Ind-Swift Laboratories to hold 30th AGM on 29 September 2025; announces book closure

Promoter & Group Acquire 39.46 Lakh Shares of Ind-Swift Labs

Promoter Group acquires 45.15 lakh shares of Ind-Swift Laboratories post-amalgamation

INDSWFTLAB Allots 81,24,698 Equity Shares Pursuant to Amalgamation Scheme

Ind-Swift Laboratories Board re-appoints auditors, schedules 30th AGM for 29th September 2025

INDSWFTLAB Allots 11,00,000 Equity Shares on Warrant Conversion

NCLT Approves Amalgamation Scheme for Ind-Swift Laboratories Limited

HCP Investments acquires 6.20% equity in Ind-Swift Laboratories

Essix Biosciences acquires 7 lakh equity shares in Ind-Swift Laboratories through warrant conversion